FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W97046304> ?p ?o ?g. }

• W97046304 endingPage "383" @default.
• W97046304 startingPage "376" @default.
• W97046304 abstract "Background Cardiovascular diseases are the most frequent cause of morbidity and mortality worldwide. Among the most important cardiovascular diseases are atherothrombosis and venous thromboembolism that present platelet aggregation as a key event. Currently, the commercial antiplatelet agents display several undesirable effects, which prompt the search for new compounds with better therapeutic index, more efficient body distribution and mechanism. Methods In this work we characterized in vivo and in vitro the antithrombotic and toxicological profiles of novel antiplatelet N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides derivatives also comparing them with aspirin. In addition we also analyzed the stability of the more active compound after encapsulation in PLGA or PCL nanoparticles and the release profile of these new nanosystems. Results The biological results revealed not only the selective effect against arachidonic acid-induced platelet aggregation mainly for compounds 2c, 2e and 2 h but also their in vivo active profile on thromboembolism pulmonary animal model with better survival rates (e.g. 82%) than aspirin (33%). The overall toxicological profile was determined by in vitro (MTT reduction tests, neutral red uptake in kidney VERO cells and hemolysis assays) and in vivo (pulmonary embolism) assays that pointed 2c as the most promising derivative with potential as a lead compound. By using the nanoprecipitation technique 2c was loaded into PLGA and PCL nanoparticles showing controlled release profile over 21 days according to our drug release tests. Conclusion According to our results compound 2c is the most interesting derivative for further studies as it showed the best activity and toxicological profile also allowing the nanoencapsulation process. Thus 2c may assist in determining a new potential therapy with favorable pharmacokinetics for treatment of thrombotic disorders." @default.
• W97046304 created "2016-06-24" @default.
• W97046304 creator A5003281264 @default.
• W97046304 creator A5012827558 @default.
• W97046304 creator A5025383552 @default.
• W97046304 creator A5039382140 @default.
• W97046304 creator A5041102678 @default.
• W97046304 creator A5041842513 @default.
• W97046304 creator A5045841044 @default.
• W97046304 creator A5058417774 @default.
• W97046304 creator A5061705726 @default.
• W97046304 creator A5064204540 @default.
• W97046304 creator A5073573487 @default.
• W97046304 creator A5087316698 @default.
• W97046304 date "2014-08-01" @default.
• W97046304 modified "2023-10-15" @default.
• W97046304 title "In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems" @default.
• W97046304 cites W1523269271 @default.
• W97046304 cites W1581870303 @default.
• W97046304 cites W1964251354 @default.
• W97046304 cites W1966891545 @default.
• W97046304 cites W1967076228 @default.
• W97046304 cites W1968677038 @default.
• W97046304 cites W1973274829 @default.
• W97046304 cites W1978119015 @default.
• W97046304 cites W1981581818 @default.
• W97046304 cites W1982974605 @default.
• W97046304 cites W1985374860 @default.
• W97046304 cites W1985933383 @default.
• W97046304 cites W1986286007 @default.
• W97046304 cites W1998688476 @default.
• W97046304 cites W2002490907 @default.
• W97046304 cites W2004674357 @default.
• W97046304 cites W2007025545 @default.
• W97046304 cites W2014680165 @default.
• W97046304 cites W2015334077 @default.
• W97046304 cites W2017451930 @default.
• W97046304 cites W2030181238 @default.
• W97046304 cites W2033391661 @default.
• W97046304 cites W2040737693 @default.
• W97046304 cites W2043603796 @default.
• W97046304 cites W2044872933 @default.
• W97046304 cites W2049382198 @default.
• W97046304 cites W2054546290 @default.
• W97046304 cites W2058028010 @default.
• W97046304 cites W2065031597 @default.
• W97046304 cites W2065302847 @default.
• W97046304 cites W2066685510 @default.
• W97046304 cites W2069800266 @default.
• W97046304 cites W2071270163 @default.
• W97046304 cites W2078328099 @default.
• W97046304 cites W2081938664 @default.
• W97046304 cites W2086069830 @default.
• W97046304 cites W2088686339 @default.
• W97046304 cites W2089773350 @default.
• W97046304 cites W2092296830 @default.
• W97046304 cites W2094087997 @default.
• W97046304 cites W2094165764 @default.
• W97046304 cites W2096196478 @default.
• W97046304 cites W2100121002 @default.
• W97046304 cites W2128616793 @default.
• W97046304 cites W2134368659 @default.
• W97046304 cites W2138281910 @default.
• W97046304 cites W2142573695 @default.
• W97046304 cites W2151412087 @default.
• W97046304 cites W2154043786 @default.
• W97046304 cites W2156627040 @default.
• W97046304 cites W2169266471 @default.
• W97046304 cites W2418681735 @default.
• W97046304 cites W4230908322 @default.
• W97046304 cites W4239886658 @default.
• W97046304 cites W4254844556 @default.
• W97046304 cites W4362029913 @default.
• W97046304 doi "https://doi.org/10.1016/j.thromres.2014.05.009" @default.
• W97046304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24877647" @default.
• W97046304 hasPublicationYear "2014" @default.
• W97046304 type Work @default.
• W97046304 sameAs 97046304 @default.
• W97046304 citedByCount "31" @default.
• W97046304 countsByYear W970463042015 @default.
• W97046304 countsByYear W970463042016 @default.
• W97046304 countsByYear W970463042017 @default.
• W97046304 countsByYear W970463042018 @default.
• W97046304 countsByYear W970463042019 @default.
• W97046304 countsByYear W970463042020 @default.
• W97046304 countsByYear W970463042021 @default.
• W97046304 countsByYear W970463042022 @default.
• W97046304 countsByYear W970463042023 @default.
• W97046304 crossrefType "journal-article" @default.
• W97046304 hasAuthorship W97046304A5003281264 @default.
• W97046304 hasAuthorship W97046304A5012827558 @default.
• W97046304 hasAuthorship W97046304A5025383552 @default.
• W97046304 hasAuthorship W97046304A5039382140 @default.
• W97046304 hasAuthorship W97046304A5041102678 @default.
• W97046304 hasAuthorship W97046304A5041842513 @default.
• W97046304 hasAuthorship W97046304A5045841044 @default.
• W97046304 hasAuthorship W97046304A5058417774 @default.
• W97046304 hasAuthorship W97046304A5061705726 @default.

• next